Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,571.20 +0.73%
EUR-USD 1.2569 0.1087%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 90.86 +0.22%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: London
  • Sector: Technology
  • Industry: Software
  • Sub-Industry: Applications Software

Instem PLC

Add to Portfolio

INS:LN

162.5000 GBp 0.00000.00%

As of 11:35:00 ET on 05/25/2012.

Snapshot for Instem PLC (INS)

Open: 162.5000 Day's Range: 162.5000 - 162.5000 Volume: 0 Bid: 158.0000
Previous Close: 162.5000 52wk Range: 159.0000 - 234.0000 1-Yr Rtn: -27.29% Ask: 167.0000

Stock Chart for INS

No chart data available.
  • INS:LN 162.5000
  • 1D
  • 1M
  • 1Y
162.5000
Interactive INS Chart

Previous Close

Key Statistics for INS

Current P/E Ratio (ttm) 18.9218
Estimated P/E (12/2012) 13.3197
Earnings Per Share (GBP) (ttm) 0.0859
Est. EPS (GBP) (12/2012) 0.1220
Est. PEG Ratio -
Market Cap (M GBP) 19.12
Shares Outstanding (M) 11.76
Enterprise Value (M GBP) (ttm) 16.00
Enterprise Value/EBITDA (ttm) 7.88
Price/Book (mrq) 3.5160
Price/Sale (ttm) 1.7637
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 09/21/2012
More INS Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for INS

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)
More INS Income Statement Data
  • Total Assets
  • Total Liabilities (M/GBP)
  • Debt to Assets (%)
More INS Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/GBP)
More INS Cash Flow Data

Company Profile & Key Executives for INS

Instem PLC provides information technology applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.

David GareChairmanPhilip John Reason "Phil"Chief Executive Officer
Nigel J GoldsmithChief Financial OfficerMichael Harwood "Mike"Senior VP:Toxicology & Path
More Company Profile & Key Executives for INS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement

Press Releases for INS

More INS Press Release
Advertisement
Advertisements